SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
Ozempic Public Funding Approval in Portugal: Key Insights and Implications
Ozempic public funding is now approved in Portugal for specific adults with type 2 diabetes. Infarmed's recent decision reimburses semaglutide (Ozempic) through the National Health Service (SNS). It targets those with inadequately controlled type 2 diabetes, BMI ≥30 kg/m², or high cardiovascular ...
Surge in Obesity Intervention Costs in the Netherlands
Obesity intervention costs in the Netherlands have skyrocketed, with a Zorginstituut Nederland report detailing a €61.8 million rise from 2021 to 2024 ...
Enhancing Patient Safety in Africa’s Healthcare Transformation
Prioritizing Patient Safety Africa in 2026 Trends
Patient safety Africa stands at the forefront as regulatory bodies drive healthcare self-reliance amid global shifts. A recent article (linked below) outlines five pivotal trends pro...